News

Becker's Hospital Review10h
After patient’s death, study cites potential barrier to Elevidys
A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...